Fouad Namouni
Net worth: - $ as of 30/05/2026
Net worth: - $ as of 30/05/2026
Dr. Fouad Namouni, MD, is a President-Research & Development at Blueprint Medicines Corp. and an Independent Director at Aprea Therapeutics, Inc. He is on the Board of Directors at Aprea Therapeutics, Inc. Dr. Namouni was previously employed as a Head-Oncology Development by Bristol Myers Squibb Co.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
VOR BIOPHARMA, INC. -.--% | 10/06/2026 | 0 ( -.--% ) | - $ | 30/05/2026 |
| Companies | Position | Start |
|---|---|---|
| VOR BIOPHARMA INC. | Director/Board Member | 29/04/2024 |
| Companies | Position | End |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Chief Tech/Sci/R&D Officer | 30/09/2025 |
| APREA THERAPEUTICS, INC. | Director/Board Member | 15/05/2022 |
| BRISTOL-MYERS SQUIBB COMPANY | Chief Tech/Sci/R&D Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Université de Paris XI Paris Sud
Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université de Paris 5 René Descartes
Université de Paris 5 René Descartes Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Vor Biopharma, Inc.
Vor Biopharma, Inc. BiotechnologyHealth Technology Engages in developing cell therapies | Health Technology |
Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops novel anticancer compounds | Health Technology |
Select your edition
All financial news and data tailored to specific country editions